 |
5 Diseases |  |
2 Trials |
|
2 Trials |  |
7 News |  |
- || albenatide (CJC-1134-PC) / ConjuChem
Clinical, PK/PD data, Journal: Safety, tolerability, pharmacodynamics and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects. (Pubmed Central) - Feb 12, 2022
The safety and PK/PD profiles of weekly CJC-1134-PC doses support Phase II studies with guidance on optimal dose selection. The clinical trial registration number for this work is ChiCTR-IPC-15007190.
- albenatide (CJC-1134-PC) / ConjuChem, Changshan Kaijiejian Biopharma
Trial primary completion date, Monotherapy: Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy (clinicaltrials.gov) - Jul 19, 2017
P2, N=73, Terminated, Sponsor: ConjuChem
The clinical trial registration number for this work is ChiCTR-IPC-15007190. Trial primary completion date: Dec 2012 --> May 2012
- | albenatide (CJC-1134-PC) / ConjuChem, Changshan Kaijiejian Biopharma
Trial termination, Monotherapy: Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy (clinicaltrials.gov) - Mar 7, 2012
P2, N=74, Terminated, Sponsor: ConjuChem
Trial primary completion date: Dec 2012 --> May 2012 Recruiting --> Terminated; Business decision
- albenatide (CJC-1134-PC) / ConjuChem, Changshan Kaijiejian Biopharma
Enrollment change, Monotherapy: Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy (clinicaltrials.gov) - Mar 7, 2012
P2, N=74, Terminated, Sponsor: ConjuChem
Recruiting --> Terminated; Business decision N=225 --> 74
- | albenatide (CJC-1134-PC) / ConjuChem, Changshan Kaijiejian Biopharma
New P2 trial, Monotherapy: Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy (clinicaltrials.gov) - Oct 19, 2011
P2, N=74, Terminated, Sponsor: ConjuChem